GREY:ATBPF - Post by User
Comment by
Rayzzeron Mar 12, 2018 7:02pm
![](https://assets.stockhouse.com/kentico-cms/0342-00/images/Sprite.svg#id_Post_Views_Icon)
274 Views
Post# 27703634
RE:Welcome all newcomers
RE:Welcome all newcomersNewcomers may also like to view this research report from Zacks SCR. The report currently values the company at $0.85 per share. Keep in mind this valuation is very conservative and uses these assumptions:
1. based on only one ( ATB-346 ) of 3 drugs in the pipeline.
2. based on only one approved indication - osteoarthritis
3. based on only 6% market share in the USA and EU of the one indication
4. based on a 50% chance of approval
https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2018/VATE-Final-Subject-Enrolled-in-Phase-2b-Trial-of-ATB-346-Data-Expected-in-March-2018-article/
StrikingMoose wrote: I knew this day would come!
The most important DD you can do in this company is watch this video of the scientific head speaking to a group of doctors about their drug pipeline
https://www.youtube.com/watch?v=w_3heP7ol0A
Review the science team and see how great they are.
They have enough money to make it through the next trial.
They are planning partnership agreements IMMEDIATELY after the results of this upcoming trial.
The next 2 weeks should be life changing for anyone holding!